Islet cells that hide from the immune system: an early but real first
On 7 January 2025 Sana reported the first person with type 1 to receive gene-engineered islet cells that made insulin for four weeks, with no immune drugs.
On 7 January 2025 a company called Sana reported a genuine first: a person with type 1 diabetes received donor insulin-making cells that had been gene-engineered to hide from the immune system, and those cells survived and kept making insulin for four weeks with no anti-rejection drugs at all. That last part is why it made headlines. It is also very early, one person followed for four weeks, so it is proof that the idea can work, not a treatment you can ask for.
- Islet cells are the clusters in the pancreas that make insulin; type 1 destroys your own, so transplanting working ones is one route people mean when they say cure.
- Transplanted cells normally need lifelong anti-rejection drugs (immunosuppression) so the immune system does not destroy them, and those drugs carry real risks of their own.
- Sana engineered these cells to be hypoimmune, meaning hidden from the immune system, so this person needed no anti-rejection drugs.
- The team confirmed the cells were alive and working by measuring C-peptide, a marker the body releases whenever insulin is made.
- This changes nothing about type 1 care today, and any NHS use would be many years and much larger trials away.
A first that turned on one detail
Islet transplants already exist, including on the NHS, but they are reserved for a small number of people whose hypos have become so severe and unpredictable that they are dangerous. The reason they are not offered more widely is the anti-rejection drugs. To stop the body destroying donated cells, a person has to take immune-suppressing medication for as long as the cells last, and that trade, swapping one serious problem for the risks of a dampened immune system, only makes sense for the most severe cases.
Sana’s report is interesting because it goes straight at that problem. The donor cells were altered so the immune system does not recognise them as foreign in the first place. In this first person, the cells were still detectable and still producing insulin four weeks after the transplant, without a single dose of immune-suppressing medication.
Why this is a first step, not a finish line
It is worth being clear-eyed about the scale. This was one person, and four weeks is a very short window in transplant terms. It tells us the cells can survive and work in a human body without anti-rejection drugs for at least that long. It does not yet tell us whether they keep working for months or years, whether the immune system finds them eventually, or whether someone could ever come off insulin entirely.
People with type 1 have heard a lot of hopeful headlines over the years, and healthy scepticism is fair. What makes this one worth noting is not that a cure has arrived, because it has not. It is that a long-standing roadblock, the need for lifelong immunosuppression, was tackled directly and, in one person for one month, cleared. That is a real direction of travel, and the thing to watch next is whether it lasts.